VivoSeq
Oncology

Colon Cancer

1

Pipeline Programs↗

19

Active Trials↗

7

Companies Involved↗

Colon Cancer is an early-stage landscape with 1 program across 7 companies. The most active players are Roche, Asahi Kasei Pharma Corporation, GSK.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

68/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

0 programs

PreclinicalA

Asahi Kasei Pharma Corporation

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalM

Medigen Biotechnology Corporation

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Epigallocatechin Gallate (EGCG)

The University of Texas Health Science Center at San Antonio

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

76

clinical trials

Completed32 · 42%
Recruiting13 · 17%
Terminated13 · 17%
Unknown status10 · 13%
Active, not recruiting3 · 4%
Not yet recruiting2 · 3%
Other3 · 4%

Clinical Trials

Trial Activity

76 trials

The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05961709·50 enrolled
Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
Recruiting·UUniversity of Iowa·Phase 2·NCT05239546·25 enrolled
Fluorescence Lymph Node Mapping for Colon Cancer Surgery
Recruiting·PPusan National University Yangsan Hospital·Phase 2·NCT07060443·186 enrolled
Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk
Recruiting·UUniversity Hospital, Rouen·Phase 3·NCT02945033·264 enrolled
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Recruiting·GSK logoGSK·Phase 3·NCT05855200·892 enrolled
A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study
Recruiting·MMedigen Biotechnology Corporation·Phase 1·NCT05394714·18 enrolled
A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Recruiting·Qilu Pharmaceutical Co., Ltd. logoQilu Pharmaceutical Co., Ltd.·Phase 3·NCT06686576·363 enrolled
Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer
Recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT06830239·10 enrolled
Butyrophilins Role in Colon Cancer
Recruiting·IInstitut Paoli-Calmettes·N/A·NCT04185272·200 enrolled
Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer Using Zebra Fish Avatars
Recruiting·UUniversity Hospital, Linkoeping·Phase 1/2·NCT06270017·300 enrolled
Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
Recruiting·SSun Yat-sen University·Phase 3·NCT05194878·840 enrolled
Genomic Services Research Program
Recruiting·NNational Human Genome Research Institute (NHGRI)·N/A·NCT02595957·5,000 enrolled
Machine Learning-Based Exosomal microRNA Signature for Preoperative Staging and Chemotherapy Eligibility in Colon Cancer
Recruiting·CCity of Hope Medical Center·N/A·NCT07255729·400 enrolled
Anesthesia and Cancer Study: Colon Cancer
Active, not recruiting·SSeoul National University Hospital·N/A·NCT04259398·797 enrolled
A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients
Active, not recruiting·LLeiden University·Phase 3·NCT02301286·770 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)